CB1 Allosteric Modulators: Molecular, Cellular and In Vivo Pharmacology

CB1 变构调节剂：分子、细胞和体内药理学

• 批准号: 9259973
• 负责人: DEBRA A KENDALL
• 金额: $ 49.87万
• 依托单位: UNIVERSITY OF CONNECTICUT STORRS
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-15 至 2021-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9259973
• 关键词: 2-arachidonylglycerol; Active Sites; Adverse effects; Affinity; Agonist; Amides; Animal Model; Arrestins; Attenuated; Behavior; Behavioral Model; Binding; Binding Sites; Biochemistry; Biological; Biological Assay; Biology; Brain; CNR1 gene; CNR2 gene; Cannabinoids; Cannabis sativa plant; Central Nervous System Diseases; Complex; Coupled; Coupling; Development; Disease; Dissociation; Drug Addiction; Drug abuse; Eating Disorders; Endocannabinoids; Equilibrium; Feeding behaviors; G-Protein-Coupled Receptors; G-substrate; GTP-Binding Protein alpha Subunits, Gs; GTP-Binding Proteins; Goals; Incidence; Indoles; Inflammation; Knowledge; Laboratories; Lead; Ligand Binding; Ligands; Mediating; Memory; Memory impairment; Metabolic syndrome; Molecular; Molecular Profiling; Mus; Neuraxis; Nicotine; Outcome; Outcome Study; Pain; Pathway interactions; Pattern; Pharmaceutical Chemistry; Pharmacology; Phosphorylation; Physiological Processes; Plants; Process; Property; Regulation; Research; Rewards; Signal Pathway; Signal Transduction; Site; Structure-Activity Relationship; Substance Addiction; Substance abuse problem; Synaptic Transmission; System; Testing; Therapeutic; Therapeutic Agents; Translating; Work; anandamide; behavioral pharmacology; cannabimimetics; cannabinoid receptor; design; drug discrimination; energy balance; feeding; functional group; improved; in vivo; mRNA Expression; mouse model; novel; painful neuropathy; positive allosteric modulator; public health relevance; pyridine; receptor; receptor binding; response; scaffold; targeted treatment; therapeutic target

 DESCRIPTION (provided by applicant): The cannabinoid receptor CB1 is a G-protein coupled receptor (GPCR) that regulates neural transmission and other physiological processes. CB1 is activated by endogenous ligands (e.g. arachidonoyl ethanolamide (AEA) and 2-arachidonoyl glycerol (2-AG)) and various synthetic and plant-derived ligands that bind to the receptor orthosteric site. These CB1 orthosteric ligands transduce signals to downstream effectors primarily via Gi/o coupling, but Gs and arrestin coupling are also possible. The biological responses are implicated in many therapeutic applications, such as substance addiction, pain and inflammation, memory, and feeding and energy balance. Recently, allosteric modulators for GPCRs were discovered. Whereas positive allosteric modulators (PAMs) enhance the functional efficacy of orthosteric agonists, negative allosteric modulators (NAMs) non-competitively decrease the activity of the receptor. These modulators bind GPCR regions topographically distinct from the orthosteric ligand binding sites and thereby exert their modulatory effects in a highly subtype specific manner. CB1 NAMs offer exciting opportunities for developing therapeutics for drug addiction and metabolic syndromes and PAMs open a new pathway to treat pain-related conditions with a reduced incidence of unwanted psychotropic effects. However, the underlying mechanisms for CB1 allosteric modulation, including for allosteric-modulation biased downstream signaling, remain elusive. We have designed and synthesized highly potent PAMs, such as LDK 1256 (KB = 89 nM), and with high allostery, such as LDK1258 (=24.5), for enhanced agonist binding. We also have identified NAMs that are the only known modulators for reducing agonist binding to CB1. We have discovered that the CB1 allosteric modulator ORG27569 is coupled to an arrestin signaling pathway, which represents the first example of a CB1 biased allosteric modulator. In this project, we will synthesize compounds through optimizing the properties of identified allosteric modulators, develop new scaffolds and identify pharmacophoric groups that improve the equilibrium dissociation constants and cooperativity factors. These compounds will be tested for impact on agonist and inverse agonist binding. We will also elucidate their G-protein and arrestin coupling and downstream molecular-level activities. In an iterative process, key CB1 modulators will be fine tuned via structure-activity relationship (SAR) analysis. We will evaluate potent allosteric modulators for their impact on CB1 pharmacological responses in vivo. This effort involves assessing key CB1 allosteric modulators versus orthosteric compounds in functional assays including in the cannabinoid tetrad and drug discrimination assays. We will also test lead ligands in mouse models of neuropathic pain, feeding, and nicotine reward. The overall goal of this work is to identify new PAMs and NAMs, elucidate their molecular level profiles, and test lead ligands in animal models. These efforts are critical for elucidating the basis of CB1 allosteric modulation so that ultimately highly specific responses can be attained via therapeutic agents.

 描述（由申请人提供）：大麻素受体CB 1是一种G蛋白偶联受体（GPCR），可调节神经传递和其他生理过程。CB 1被内源性配体（例如花生四烯酰乙醇酰胺（AEA）和2-花生四烯酰甘油（2-AG））以及结合受体正构位点的各种合成和植物衍生配体激活。这些CB 1正构配体主要通过Gi/o偶联将信号传递给下游效应子，但Gs和抑制蛋白偶联也是可能的。生物学反应涉及许多治疗应用，例如物质成瘾、疼痛和炎症、记忆、进食和能量平衡。最近，发现了GPCR的变构调节剂。正变构调节剂（PAM）增强正构激动剂的功能功效，而负变构调节剂（NAM）非竞争性地降低受体的活性。这些调节剂结合与正构配体结合位点在形貌上不同的GPCR区域，从而以高度亚型特异性的方式发挥其调节作用。CB 1 NAM为开发药物成瘾和代谢综合征的治疗方法提供了令人兴奋的机会，PAM开辟了治疗疼痛相关疾病的新途径，降低了不必要的精神影响的发生率。然而，CB 1变构调节的潜在机制，包括变构调节偏向下游信号传导，仍然难以捉摸。我们设计并合成了高效PAM，如LDK 1256（KB = 89 nM），并具有高变构性，如LDK 1258（KB =24.5），用于增强激动剂结合。我们还鉴定了NAM，其是唯一已知的用于减少激动剂与CB 1结合的调节剂。我们发现CB 1变构调节剂ORG 27569与抑制蛋白信号通路偶联，这代表了CB 1偏向变构调节剂的第一个例子。在这个项目中，我们将通过优化已确定的变构调节剂的性质来合成化合物，开发新的支架，并确定提高平衡解离常数和协同因子的药效基团。将检测这些化合物对激动剂和反向激动剂结合的影响。我们还将阐明它们的G蛋白和arrestin耦合和下游分子水平的活动。在迭代过程中，关键的CB 1调节剂将通过结构-活性关系（SAR）分析进行微调。我们将评估有效的变构调节剂对CB 1体内药理学反应的影响。这项工作涉及评估关键的CB 1变构调节剂与正构化合物的功能测定，包括在大麻素四分体和药物歧视测定。我们还将在神经性疼痛、进食和尼古丁奖励的小鼠模型中测试铅配体。这项工作的总体目标是确定新的PAM和NAM，阐明其分子水平的概况，并在动物模型中测试铅配体。这些努力对于阐明CB 1变构调节的基础至关重要 从而最终可以通过治疗剂获得高度特异性的应答。